As the microbiome therapeutics market is constantly drawing interest from both consumers and industry, it is moving in an entirely new direction.
The microbiome therapeutics are not limited to treatment of the digestive system disorders, an expansion in customer awareness, rising interest of big pharma companies, and intensification of primary research and clinical growth are four significant trends that are bringing a revolution in the market.
Moving forward, let us understand in-depth the microbiome and the importance of microbiome therapeutics.
Microbiome - A Brief Introduction
The microbiome meaning is defined as the set of microorganism’s communities residing on an animal or human host. As per the host site, the microbiome strains' quantity varies from a hundred to a thousand, and each of the strains contains different genes having distinct functions.
The microbiome organism is responsible for maintaining the overall health of the host and essential functions such as hosting nutrition, establishing robust innate immunity, and pathogen exclusion.
The microbiome organism is much significant for hosting individual strains and helping to fight against inflammatory and infectious diseases.
Importance of Microbiome Therapeutics
The use of conventional therapies has not helped patients much and resulted in drug non-responsiveness, poor specificity, antibiotic resistance among pathogens, and resistance to chemotherapy. These embodiments pose a danger to the human population's health. However, microbial therapy has the potential to overcome the drawbacks of current medicines or therapies.
Microbes are natural residents present in the human body that improve the body’s therapeutic capability without side effects. Moreover, the microbes also help genetically to enhance safety and efficacy in fighting against the diseases
A human gut microbiome has a crucial role in maintaining human health. On the other hand, the dysbiosis of the microbiome could lead to disease onset.
Microbes can help in overcoming the onset of several diseases by interacting directly with the host; therefore, it is necessary to develop microbiome therapeutics for treating multiple diseases such as cancer.
Microbiome therapeutics are constantly emerging as one of the healthcare sector's greatest interests, with the potential to address several clinical conditions.
According to the BIS Research market study, the global microbiome therapeutics market is expected to touch $3,204.0 million by 2032 from a market value of $306.3 million in 2021, with a growth rate of 24.95% during the forecast period 2022-2032.
Latest Development in the Microbiome Therapeutics
Recently a company named Microbiome Therapeutics Innovation Group (MTIG) announced its new chairperson, Dr. Nikole Kimes.
MTIG is one of the leading companies in the research and development of microbiome-based products and therapeutics, approved by the food and drug administration (FDA) for addressing medical needs, reducing healthcare costs, and improving clinical outcomes.
On July 5, 2022, in Washington, Microbiome Therapeutics Innovation Group announced its new chairperson, who is the chief executive officer (CEO) of Siolta Therapeutics and a Ph.D. holder, replacing Ken Blount.
Dr. Ken Blount has been serving MTIG since 2019. However, from now onward, he will be joining the board of directors and continue serving MTIG.
"It is an honor to be trusted to lead this growing coalition," said Dr. Kimes while joining MTIG. "I thank Ken for his leadership and look forward to continuing advocating for the advancement of microbiome-based therapeutics during this exciting time in the industry," further added Dr. Kimes.
Challenges Associated with Microbiome Therapeutics
Microbiome therapeutics shows native gut microbial conditions for healthy gut functioning and controlling dysregulation. The microbes, as treatment, aim to correct dysbiosis and enhance the host's survival by influencing the metabolic, physiological, and nutritional pathways.
Microbiome therapeutics is a promising therapy, but it does suffer from a few challenges. The primary challenge in the microbiome therapeutics field is to identify the microbes to manage disease complexities. Different strains of microbial are appropriate for different approaches of therapeutics based on multiple factors such as survival of the microbial strains.
Moreover, proper characterization of microbes per their functional uses requires to be accomplished before choosing them for therapy for successful results.
Also, there is a high need for several regulatory and safety issues that need to be analyzed for achieving successful clinical trials of microbiome therapeutics. However, despite such challenges, the microbiome therapeutics market is constantly growing.
According to Tausif, Principal Analyst, BIS Research, "Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives. The dominance of the gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders and cancer indications.
Microbiome therapeutics in combination with advanced healthcare techniques may aid in diseases’ therapies and several other clinical applications. However, the use of bacterial breaks has an elevated risk to the health of the patients and may result in the entry of pathogens within the recipient. Thus, strategies to bypass contamination require to be developed and used.
Companies should also now raise the manufacturing of bacteria-specific products to bypass the wide range of adverse impacts of the microbes on the patients.